A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Identifieur interne : 002509 ( PubMed/Curation ); précédent : 002508; suivant : 002510A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Auteurs : Martin Spruth [Autriche] ; Otfried Kistner ; Helga Savidis-Dacho ; Elisabeth Hitter ; Brian Crowe ; Marijan Gerencer ; Peter Brühl ; Leopold Grillberger ; Manfred Reiter ; Christa Tauer ; Wolfgang Mundt ; P Noel BarrettSource :
- Vaccine [ 0264-410X ] ; 2006.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (pharmacologie), Animaux, Anticorps antiviraux (analyse), Anticorps antiviraux (biosynthèse), Cellules Vero, Femelle, Fermentation, Immunisation, Relation dose-réponse (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Technique de Western, Techniques de culture de tissus, Test ELISA, Tests de neutralisation, Vaccins antiviraux (immunologie), Vaccins inactivés (immunologie), Virus du SRAS (immunologie), Électrophorèse sur gel de polyacrylamide.
- MESH :
- analyse : Anticorps antiviraux.
- biosynthèse : Anticorps antiviraux.
- immunologie : Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- pharmacologie : Adjuvants immunologiques.
- Animaux, Cellules Vero, Femelle, Fermentation, Immunisation, Relation dose-réponse (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Technique de Western, Techniques de culture de tissus, Test ELISA, Tests de neutralisation, Électrophorèse sur gel de polyacrylamide.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (pharmacology), Animals, Antibodies, Viral (analysis), Antibodies, Viral (biosynthesis), Blotting, Western, Chlorocebus aethiops, Dose-Response Relationship, Immunologic, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Female, Fermentation, Immunization, Mice, Mice, Inbred BALB C, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Tissue Culture Techniques, Vaccines, Inactivated (immunology), Vero Cells, Viral Vaccines (immunology).
- MESH :
- chemical , analysis : Antibodies, Viral.
- chemical , biosynthesis : Antibodies, Viral.
- chemical , immunology : Vaccines, Inactivated, Viral Vaccines.
- chemical , pharmacology : Adjuvants, Immunologic.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Blotting, Western, Chlorocebus aethiops, Dose-Response Relationship, Immunologic, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Female, Fermentation, Immunization, Mice, Mice, Inbred BALB C, Neutralization Tests, Tissue Culture Techniques, Vero Cells.
Abstract
A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)3 had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-gamma and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.
DOI: 10.1016/j.vaccine.2005.08.055
PubMed: 16214268
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002509
Links to Exploration step
pubmed:16214268Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.</title><author><name sortKey="Spruth, Martin" sort="Spruth, Martin" uniqKey="Spruth M" first="Martin" last="Spruth">Martin Spruth</name><affiliation wicri:level="1"><nlm:affiliation>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15, 2304 Orth/Donau, Austria. martin.spruth@baxter.com</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15, 2304 Orth/Donau</wicri:regionArea></affiliation></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name></author><author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name></author><author><name sortKey="Hitter, Elisabeth" sort="Hitter, Elisabeth" uniqKey="Hitter E" first="Elisabeth" last="Hitter">Elisabeth Hitter</name></author><author><name sortKey="Crowe, Brian" sort="Crowe, Brian" uniqKey="Crowe B" first="Brian" last="Crowe">Brian Crowe</name></author><author><name sortKey="Gerencer, Marijan" sort="Gerencer, Marijan" uniqKey="Gerencer M" first="Marijan" last="Gerencer">Marijan Gerencer</name></author><author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name></author><author><name sortKey="Grillberger, Leopold" sort="Grillberger, Leopold" uniqKey="Grillberger L" first="Leopold" last="Grillberger">Leopold Grillberger</name></author><author><name sortKey="Reiter, Manfred" sort="Reiter, Manfred" uniqKey="Reiter M" first="Manfred" last="Reiter">Manfred Reiter</name></author><author><name sortKey="Tauer, Christa" sort="Tauer, Christa" uniqKey="Tauer C" first="Christa" last="Tauer">Christa Tauer</name></author><author><name sortKey="Mundt, Wolfgang" sort="Mundt, Wolfgang" uniqKey="Mundt W" first="Wolfgang" last="Mundt">Wolfgang Mundt</name></author><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16214268</idno><idno type="pmid">16214268</idno><idno type="doi">10.1016/j.vaccine.2005.08.055</idno><idno type="wicri:Area/PubMed/Corpus">002509</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002509</idno><idno type="wicri:Area/PubMed/Curation">002509</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002509</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.</title><author><name sortKey="Spruth, Martin" sort="Spruth, Martin" uniqKey="Spruth M" first="Martin" last="Spruth">Martin Spruth</name><affiliation wicri:level="1"><nlm:affiliation>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15, 2304 Orth/Donau, Austria. martin.spruth@baxter.com</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15, 2304 Orth/Donau</wicri:regionArea></affiliation></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name></author><author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name></author><author><name sortKey="Hitter, Elisabeth" sort="Hitter, Elisabeth" uniqKey="Hitter E" first="Elisabeth" last="Hitter">Elisabeth Hitter</name></author><author><name sortKey="Crowe, Brian" sort="Crowe, Brian" uniqKey="Crowe B" first="Brian" last="Crowe">Brian Crowe</name></author><author><name sortKey="Gerencer, Marijan" sort="Gerencer, Marijan" uniqKey="Gerencer M" first="Marijan" last="Gerencer">Marijan Gerencer</name></author><author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name></author><author><name sortKey="Grillberger, Leopold" sort="Grillberger, Leopold" uniqKey="Grillberger L" first="Leopold" last="Grillberger">Leopold Grillberger</name></author><author><name sortKey="Reiter, Manfred" sort="Reiter, Manfred" uniqKey="Reiter M" first="Manfred" last="Reiter">Manfred Reiter</name></author><author><name sortKey="Tauer, Christa" sort="Tauer, Christa" uniqKey="Tauer C" first="Christa" last="Tauer">Christa Tauer</name></author><author><name sortKey="Mundt, Wolfgang" sort="Mundt, Wolfgang" uniqKey="Mundt W" first="Wolfgang" last="Mundt">Wolfgang Mundt</name></author><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (pharmacology)</term><term>Animals</term><term>Antibodies, Viral (analysis)</term><term>Antibodies, Viral (biosynthesis)</term><term>Blotting, Western</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Immunologic</term><term>Electrophoresis, Polyacrylamide Gel</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Fermentation</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Tissue Culture Techniques</term><term>Vaccines, Inactivated (immunology)</term><term>Vero Cells</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (pharmacologie)</term><term>Animaux</term><term>Anticorps antiviraux (analyse)</term><term>Anticorps antiviraux (biosynthèse)</term><term>Cellules Vero</term><term>Femelle</term><term>Fermentation</term><term>Immunisation</term><term>Relation dose-réponse (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Technique de Western</term><term>Techniques de culture de tissus</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term><term>Électrophorèse sur gel de polyacrylamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Blotting, Western</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Immunologic</term><term>Electrophoresis, Polyacrylamide Gel</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Fermentation</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Tissue Culture Techniques</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Femelle</term><term>Fermentation</term><term>Immunisation</term><term>Relation dose-réponse (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Technique de Western</term><term>Techniques de culture de tissus</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Électrophorèse sur gel de polyacrylamide</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)3 had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-gamma and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16214268</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.</ArticleTitle><Pagination><MedlinePgn>652-61</MedlinePgn></Pagination><Abstract><AbstractText>A double-inactivated, candidate whole virus vaccine against severe acute respiratory syndrome associated coronavirus (SARS-CoV) was developed and manufactured at large scale using fermenter cultures of serum protein free Vero cells. A two step inactivation procedure involving sequential formaldehyde and U.V. inactivation was utilised in order to ensure an extremely high safety margin with respect to residual infectivity. The immunogenicity of this double-inactivated vaccine was characterised in the mouse model. Mice that were immunised twice with the candidate SARS-CoV vaccine developed high antibody titres against the SARS-CoV spike protein and high levels of neutralising antibodies. The use of the adjuvant Al(OH)3 had only a minor effect on the immunogenicity of the vaccine. In addition, cell mediated immunity as measured by interferon-gamma and interleukin-4 stimulation, was elicited by vaccination. Moreover, the vaccine confers protective immunity as demonstrated by prevention of SARS-CoV replication in the respiratory tract of mice after intranasal challenge with SARS-CoV. Protection of mice was correlated to antibody titre against the SARS-CoV S protein and neutralising antibody titre.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spruth</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Baxter Vaccines, Biomedical Research Centre, Uferstr. 15, 2304 Orth/Donau, Austria. martin.spruth@baxter.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kistner</LastName><ForeName>Otfried</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Savidis-Dacho</LastName><ForeName>Helga</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hitter</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gerencer</LastName><ForeName>Marijan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brühl</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Grillberger</LastName><ForeName>Leopold</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Reiter</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tauer</LastName><ForeName>Christa</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mundt</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>P Noel</ForeName><Initials>PN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01AI30038</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AI-30038</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046509" MajorTopicYN="N">Tissue Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId><ArticleId IdType="pii">S0264-410X(05)00867-4</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2005.08.055</ArticleId><ArticleId IdType="pmc">PMC7115667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anal Biochem. 1976 May 7;72:248-54</Citation><ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Dev Biol Stand. 1993;81:103-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8174792</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int Immunol. 2004 Oct;16(10):1423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15314040</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 1998 May-Jun;16(9-10):960-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9682344</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 1999 Apr;41(3):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10320047</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2002 May 31;20 Suppl 3:S34-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12184362</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vet Microbiol. 1993 Jul;36(1-2):1-37</Citation><ArticleIdList><ArticleId IdType="pubmed">8236772</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2269-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15755609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002509 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002509 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16214268
|texte= A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16214268" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |